BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21953839)

  • 21. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands.
    Heitman LH; Ijzerman AP
    Med Res Rev; 2008 Nov; 28(6):975-1011. PubMed ID: 18561294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
    Li H; Anderes KL; Kraynov EA; Luthin DR; Do QQ; Hong Y; Tompkins E; Sun ET; Rajapakse R; Pathak VP; Christie LC; Feng J; Vazir H; Castillo R; Gregory ML; Castro M; Nared-Hood K; Paderes G; Anderson MB
    J Med Chem; 2006 Jun; 49(11):3362-7. PubMed ID: 16722655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Betidamino acid scan of the GnRH antagonist acyline.
    Jiang G; Miller C; Koerber SC; Porter J; Craig AG; Bhattacharjee S; Kraft P; Burris TP; Campen CA; Rivier CL; Rivier JE
    J Med Chem; 1997 Nov; 40(23):3739-48. PubMed ID: 9371239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
    Kim SM; Lee M; Lee SY; Lee SM; Kim EJ; Kim JS; Ann J; Lee J; Lee J
    Eur J Med Chem; 2018 Feb; 145():413-424. PubMed ID: 29335207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone effects on luteinizing hormone and follicle-stimulating hormone responses to gonadotropin-releasing hormone in the mouse.
    Huang BM; Leu SF; Yang HY; Norman RL
    J Androl; 2001; 22(3):507-13. PubMed ID: 11330652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic suppression of the ovarian function and its clinical usefulness].
    Kershenovich Sefchovich R; Kably Ambe A; García Morales MA; Peryra Quiñones R; Barrón Vallejo J
    Ginecol Obstet Mex; 1997 Aug; 65():344-8. PubMed ID: 9324471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
    Jiang G; Stalewski J; Galyean R; Dykert J; Schteingart C; Broqua P; Aebi A; Aubert ML; Semple G; Robson P; Akinsanya K; Haigh R; Riviere P; Trojnar J; Junien JL; Rivier JE
    J Med Chem; 2001 Feb; 44(3):453-67. PubMed ID: 11462984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists.
    Rivier JE; Porter J; Cervini LA; Lahrichi SL; Kirby DA; Struthers RS; Koerber SC; Rivier CL
    J Med Chem; 2000 Mar; 43(5):797-806. PubMed ID: 10715148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral delivery of oil-based formulation for a novel synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for prostate cancer treatment.
    Zhang G; Wang T; Gao L; Quan D
    Int J Pharm; 2013 Jun; 450(1-2):138-44. PubMed ID: 23623791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
    Tezuka M; Tamai Y; Kuramochi Y; Kobayashi K; Fushimi N; Kiguchi S
    Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1082-1093. PubMed ID: 35690889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.
    Luthin DR; Hong Y; Tompkins E; Anderes KL; Paderes G; Kraynov EA; Castro MA; Nared-Hood KD; Castillo R; Gregory M; Vazir H; May JM; Anderson MB
    Bioorg Med Chem Lett; 2002 Dec; 12(24):3635-9. PubMed ID: 12443792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling.
    Koerber SC; Rizo J; Struthers RS; Rivier JE
    J Med Chem; 2000 Mar; 43(5):819-28. PubMed ID: 10715150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disila-galaxolide and derivatives: synthesis and olfactory characterization of silicon-containing derivatives of the musk odorant galaxolide.
    Dörrich S; Bauer JB; Lorenzen S; Mahler C; Schweeberg S; Burschka C; Baus JA; Tacke R; Kraft P
    Chemistry; 2013 Aug; 19(34):11396-408. PubMed ID: 23843352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists.
    Luthin DR; Hong Y; Pathak VP; Paderes G; Nared-Hood KD; Castro MA; Vazir H; Li H; Tompkins E; Christie L; May JM; Anderson MB
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3467-70. PubMed ID: 12419385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-(3,5-Dimethylphenyl)tryptamine derivatives that bind to the GnRH receptor.
    Lin P; Marino D; Lo JL; Yang YT; Cheng K; Smith RG; Fisher MH; Wyvratt MJ; Goulet MT
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1073-6. PubMed ID: 11327593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of novel silicon-containing inverse agonists of retinoic acid receptor-related orphan receptors.
    Toyama H; Nakamura M; Nakamura M; Matsumoto Y; Nakagomi M; Hashimoto Y
    Bioorg Med Chem; 2014 Mar; 22(6):1948-59. PubMed ID: 24559867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A bicyclic cispentacin derivative as a novel reverse turn inducer in a GnRH mimetic.
    Langer O; Kählig H; Zierler-Gould K; Bats JW; Mulzer J
    J Org Chem; 2002 Oct; 67(20):6878-83. PubMed ID: 12353977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: minimization of mechanism-based CYP3A4 inhibition.
    Hashimoto K; Kataoka M; Tatsuta M; Yasoshima K; Yamamoto M; Yura T; Yamamoto N; Urbahns K; Gupta JB; Li Y
    Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1314-7. PubMed ID: 16204990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can silicon make an excellent drug even better? An in vitro and in vivo head-to-head comparison between loperamide and its silicon analogue sila-loperamide.
    Geyer M; Wellner E; Jurva U; Saloman S; Armstrong D; Tacke R
    ChemMedChem; 2015 May; 10(5):911-24. PubMed ID: 25801200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.